Good evening :)
$
₹
Skye Bioscience, Inc. Common Stock

Skye Bioscience, Inc. Common Stock

SKYE

NASDAQ
Asset Logo

Skye Bioscience, Inc. Common Stock

SKYE

NASDAQ
$1.925.88% (-0.12)
$
₹
$1.925.88% (-0.12)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Biotechnology

Micro Cap

With a market cap of $9.0M the stock is ranked 5730

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

1.95
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-10.24
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 7 analysts' reports

Buy
7 analysts
Hold
0 analyst
Sell
0 analyst

Analysts expect a +3233.33% price upside over the next year

Current Price$1.92
Target Price$68

Company Profile

Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation. Nimacimab addresses metabolic processes related to energy expenditure, fat mobilization, leptin sensitivity, appetite regulation, and satiety signaling. Skye Bioscience, Inc. was formerly known as Emerald Bioscience Inc. and changed its name to Skye Bioscience, Inc. in December 2020. Skye Bioscience, Inc. was incorporated in 2011 and is based in San Diego, California.
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation. Nimacimab addresses metabolic processes related to energy expenditure, fat mobilization, leptin sensitivity, appetite regulation, and satiety signaling. Skye Bioscience, Inc. was formerly known as Emerald Bioscience Inc. and changed its name to Skye Bioscience, Inc. in December 2020. Skye Bioscience, Inc. was incorporated in 2011 and is based in San Diego, California.

Peers

Peers

AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
72.42
72.42
1Y Return
16.62%
16.62%
Buy Reco %
57.14
57.14
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
23.42
23.42
1Y Return
34.41%
34.41%
Buy Reco %
46.87
46.87
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
22.78%
22.78%
Buy Reco %
63.33
63.33
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
30.03
30.03
1Y Return
29.71%
29.71%
Buy Reco %
52.94
52.94
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
19.34
19.34
1Y Return
37.71%
37.71%
Buy Reco %
76.00
76.00

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Skye Bioscience, Inc. Common Stock -1.95-
AbbVie Inc72.4250.450.52
Amgen Inc23.4217.452.27

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

-12.7
-14.4
-12.5
-10.7
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue0000000000
Net Income-5.01-7.90-3.89-9.74-11.10-17.62-12.75-14.44-12.50-10.78
Net Profit Margin----------
See CostsAll values in $ Million

Frequently asked questions

Frequently asked questions

  1. Skye Bioscience, Inc. Common Stock (SKYE) share price today is $1.92 as of September 14, 2026 at 11:56 PM IST. The stock touched a day high of $2.00 and a day low of $1.89.

  2. Skye Bioscience, Inc. Common Stock stock trades on NASDAQ under the ticker symbol SKYE.

  3. Skye Bioscience, Inc. Common Stock's market capitalization is $9.03M as of September 14, 2026 at 11:56 PM IST.

  4. Skye Bioscience, Inc. Common Stock's price-to-earnings (P/E) ratio is N/A as of September 14, 2026.

  5. Skye Bioscience, Inc. Common Stock's price-to-book (P/B) ratio is 1.95 as of September 14, 2026.

  6. Yes, You can buy Skye Bioscience, Inc. Common Stock shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Skye Bioscience, Inc. Common Stock shares in three steps: 1. Search Skye Bioscience, Inc. Common Stock on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Skye Bioscience, Inc. Common Stock trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Skye Bioscience, Inc. Common Stock (SKYE) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 5.2083 shares at the current price of $1.92.

Loading...